Syndax 预计 Revuforj 在美国市场的峰值净营收将超过 20 亿美元，第四季度 axatilimab 数据公布在即 (NASDAQ:SNDX)
· seekingalpha.com
Syndax (SNDX) 2026 年第二季度财报电话会议回顾：Revuforj/Niktimvo 销售情况、20 亿+美元峰值展望、第四季度催化剂及现金流预测。
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...